Serna Bio

2:45 PM - 3:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
Founded in 2021, Serna Bio is building the first map of the druggable transcriptome, opening up the universe of RNA biology to small molecule drug discovery. Most current therapeutics target known proteins that make up only 2% of the genome, while 70% of the genome encodes RNA. This represents a significant area of biology that is yet to be explored or targeted therapeutically. The Serna Bio discovery platform generates a unique understanding of what features of small molecules alter RNA functions through a proprietary database of transcriptome wide, functional RNA structures and their small molecule RNA-binders.. Using an AI-powered platform, we are developing a pipeline of first-in-class specific and drug-like small molecules for class specific and drug-like small molecules for classically undruggable proteins and lncRNA targets. We have contributed to seminal work with a recent publication with the NCI (https://onlinelibrary.wiley.com/doi/10.1002/anie.202211358)
Company Type:
Privately Funded Company
Company Website:
Not Provided
Company HQ State:
Not Provided
Company HQ Country:
Not Provided
Year Founded:
Not Provided
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
Not Provided
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
Placeholder Photo
CEO/Founder
Serna Bio